Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives

Overview

Journal Ann Dermatol

Specialty Dermatology

Date 2024 Sep 29

PMID 39343752

Authors

Hee Joo Kim

Victoria P Werth

Affiliations

Soon will be listed here.

Abstract

Dermatomyositis (DM) is a rare autoimmune connective tissue disease with characteristic skin manifestations and possible muscle involvement. Recent advances in classification system to include skin-predominant subtypes, understanding underlying pathogenic mechanisms and the relationship between clinical phenotypes and myositis-specific autoantibodies have led to development of novel therapeutic options. This corresponds with efforts to develop better outcome measures to accurately catch the patients' current disease status and treatment-induced improvements. This report will review the updates in newer treatments and outcome measures of DM, specifically from a dermatologic point of view.

References

Ardeniz O, Unger S, Onay H, Ammann S, Keck C, Cianga C . β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. J Allergy Clin Immunol. 2015; 136(2):392-401. DOI: 10.1016/j.jaci.2014.12.1937. View

Pandya R, Dan J, Kleitsch J, White B, Werth V . Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial. J Invest Dermatol. 2023; 143(12):2378-2385.e7. DOI: 10.1016/j.jid.2023.05.025. View

Robinson E, Alves P, Bashir M, Zeidi M, Feng R, Werth V . Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro. J Invest Dermatol. 2017; 137(11):2445-2447. PMC: 5651184. DOI: 10.1016/j.jid.2017.05.035. View

Ghazi E, Sontheimer R, Werth V . The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol. 2012; 31(1):128-34. PMC: 3883437. View

Hansen R, Balthasar J . Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost. 2003; 88(6):898-9. View

Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T . Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011; 147(4):391-8. DOI: 10.1001/archdermatol.2011.52. View

Olivo Pallo P, De Souza F, Miossi R, Shinjo S . Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series. Adv Rheumatol. 2019; 58(1):34. DOI: 10.1186/s42358-018-0035-7. View

Chen K, Patel J, Zeidi M, Wysocka M, Bashir M, Patel B . Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness. J Invest Dermatol. 2021; 141(8):1906-1914.e2. PMC: 8316264. DOI: 10.1016/j.jid.2020.12.032. View

Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H . Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014; 24(4):694-6. DOI: 10.3109/14397595.2013.874762. View

10.

Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M . JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018; 141(6):1609-1621. DOI: 10.1093/brain/awy105. View

11.

Piguet V, Choy E . Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?. Br J Dermatol. 2018; 179(6):1233-1234. DOI: 10.1111/bjd.16230. View

12.

Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C . Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Front Immunol. 2022; 13:1051609. PMC: 9791086. DOI: 10.3389/fimmu.2022.1051609. View

13.

Waldman R, DeWane M, Lu J . Dermatomyositis: Diagnosis and treatment. J Am Acad Dermatol. 2019; 82(2):283-296. DOI: 10.1016/j.jaad.2019.05.105. View

14.

Lim D, Fiorentino D, Werth V . Current concepts and advances in dermatomyositis: a dermatological perspective. Clin Exp Rheumatol. 2023; 41(2):359-369. DOI: 10.55563/clinexprheumatol/ue71ku. View

15.

Werth V, Hejazi E, Pena S, Haber J, Zeidi M, Reddy N . Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. J Invest Dermatol. 2022; 142(10):2651-2659.e1. PMC: 10226779. DOI: 10.1016/j.jid.2022.03.029. View

16.

Click J, Qureshi A, Vleugels R . Methotrexate for the treatment of cutaneous dermatomyositis. J Am Acad Dermatol. 2013; 68(6):1043-5. DOI: 10.1016/j.jaad.2013.01.008. View

17.

Hornung T, Ko A, Tuting T, Bieber T, Wenzel J . Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2011; 37(2):139-42. DOI: 10.1111/j.1365-2230.2011.04188.x. View

18.

Tepper M, Zurier R, Burstein S . Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg Med Chem. 2014; 22(13):3245-51. DOI: 10.1016/j.bmc.2014.04.062. View

19.

Chung L, Genovese M, Fiorentino D . A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007; 143(6):763-7. DOI: 10.1001/archderm.143.6.763. View

20.

Ahmed S, Chen K, Werth V . The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. Semin Arthritis Rheum. 2020; 50(3):458-462. PMC: 7434515. DOI: 10.1016/j.semarthrit.2020.01.002. View